Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity
Journal of Antimicrobial Chemotherapy · 03.04.2026 · 81 (5)
DOI: 10.1093/jac/dkag138 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 17.04.2026. Verfasst von Kieffer Korvin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious and Tropical Diseases, Nimes University Hospital, Nimes, France. Hauptthemen laut MEDLINE: Cefepime, Anti-Bacterial Agents, Neurotoxicity Syndromes. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cefepime is a key carbapenem-sparing agent due to its stability against AmpC β-lactamases. However, high plasma concentrations are associated with cefepime-induced neurotoxicity (CIN). Following 2019 EUCAST reclassification of ‘intermediate’ as ‘susceptible, increased exposure’, higher doses (6 g/day) are often recommended. Pharmacokinetic/pharmacodynamic (PK/PD) simulations suggest that a reduced daily dose of cefepime 4 g/day administered by continuous infusion may achieve adequate target attainment while limiting toxicity, but real-world clinical data are scarce.
Methods
We conducted a prospective, single-centre observational study including adult inpatients treated with cefepime administered as a 2 g loading dose followed by continuous infusion of 4 g/day. Therapeutic drug monitoring was performed to assess steady-state free cefepime concentrations (ƒCss). The primary endpoint was pharmacodynamic target attainment (100% ƒT > MIC) for EUCAST ‘susceptible, increased exposure’ breakpoints.
Results
Among 46 included patients, median ƒCss was 26.2 mg/L (IQR 18.4–33.2). Pharmacodynamic targets were achieved in 96% of patients for Enterobacterales (MIC 4 mg/L) and 93% for Pseudomonas aeruginosa (MIC 8 mg/L). Clinical efficacy was observed in 96% of cases. Signs consistent with CIN occurred in three patients (6.5%), mainly in the context of renal function deterioration or pre-existing neurological vulnerability.
Conclusion
A reduced-dose cefepime regimen consisting of 4 g/day administered by continuous infusion achieves high pharmacodynamic target attainment with a favourable efficacy–toxicity balance in real-life clinical practice. This strategy represents a promising alternative to higher-dose regimens and supports individualized dosing guided by renal function and therapeutic drug monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious and Tropical Diseases, Nimes University Hospital, Nimes, France.
- CHU de Lyon, Service de Pharmacie, Groupement Hospitalier Nord, Hôpital Pierre Garraud, 136 rue du Commandant Charcot, Lyon cedex 05 69322, France.
- Laboratoire de Biométrie et Biologie Évolutive, Université Claude Bernard Lyon 1, UMR CNRS 5558, University of Lyon, Bât. Grégor Mendel, 43 bd du 11 Novembre 1918, Villeurbanne Cedex 69622, France.
- ISPB-Faculté de Pharmacie de Lyon, Université Claude Bernard Lyon 1, University of Lyon, 8 Avenue Rockefeller, Lyon 69003, France.
- Department of Pharmacy, Nimes University Hospital, Nimes, France.
- VBIC, Univ Montpellier, INSERM, Nimes, France.
ORCID-Profile: Sylvain Goutelle, Paul Loubet, Romaric Larcher
Zitieren
APA
Korvin, K., Goutelle, S., Laffont-Lozes, P., Villa, F., Martin, A., Chiaruzzi, M., Loubet, P., Sotto, A., & Larcher, R. (2026). Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity. Journal of Antimicrobial Chemotherapy, 81(5). https://doi.org/10.1093/jac/dkag138
Vancouver
Korvin K, Goutelle S, Laffont-Lozes P, Villa F, Martin A, Chiaruzzi M, et al. Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity. Journal of Antimicrobial Chemotherapy. 2026;81(5). doi:10.1093/jac/dkag138
BibTeX
@article{Korvin2026,
author = {Korvin, Kieffer and Goutelle, Sylvain and Laffont-Lozes, Paul and Villa, Fanny and Martin, Aurélie and Chiaruzzi, Myriam and Loubet, Paul and Sotto, Albert and Larcher, Romaric},
title = {Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {5},
doi = {10.1093/jac/dkag138}
}
EUVIMED